Elderly diabetics taking the drug rosiglitazone, which is sold under the brand name Avandia, face a greater risk of developing congestive heart failure a Harvard Medical School report has found, according to the New York Times, "Diabetes Drug Linked To Higher Rate Of Death." The study tracked 28,361 Medicare beneficiaries for up to five years and found that death rates were 15% higher and incidents of congestive heart failure 13% higher for those treated with rosiglitazone compared with those taking pioglitazone.
Robert L. Abell
Comments